SARASOTA, Fla., March 22,
2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:
INVO), a commercial-stage fertility company focused on expanding
access to advanced treatment worldwide with its INVOcell® medical
device and the IVC procedure it enables, announced today that
Inger Britt Carlsson, PhD, INVO
Bioscience's Vice President of Medical Affairs, will participate in
a roundtable discussion at the 2022 Virtual Growth Conference,
presented by Maxim Group LLC and hosted by M-Vest.
The roundtable, titled "Advances in Women's Health: From
Clinical to Commercial" will be webcast live on Monday, March 28th at 3:00pm. Participants will also include executives
from other leading women's health companies.
The roundtable and presentation may be viewed by registering at
the following conference page - Virtual Growth Conference
Registration.
Maxim's Virtual Growth Conference
During this virtual conference, investors will hear from
executives from a wide range of sectors including Biotech, Clean
Energy, Electric Vehicles, Financial Services, Fintech & REITS,
Gaming & Entertainment, Healthcare, Healthcare IT,
Infrastructure, Shipping and Technology/ Media/Telecom. The
conference will feature company presentations, fireside chats,
roundtable discussions, and live Q&A with CEOs moderated by
Maxim Research Analysts. This conference will be live on M-Vest. To
attend, just sign up to become an M-Vest member. Click Here to
Reserve your seat
About INVO Bioscience
We are a commercial-stage fertility company expanding access to
advanced treatment worldwide. Our primary mission is to implement
new medical technologies aimed at increasing the availability of
affordable, high-quality, patient-centered fertility care. Our
patented medical device, the INVOcell®, enables a revolutionary
in vivo method of vaginal incubation. This treatment
solution is the world's first intravaginal culture technique for
the incubation of oocytes and sperm during fertilization and
early embryo development. This technique, designated as "IVC,"
provides patients a more natural and intimate experience in
comparison to other assisted reproductive technology (ART)
treatments. The IVC procedure can deliver comparable results at a
fraction of the cost of traditional in vitro fertilization
(IVF) and is a significantly more effective treatment than
intrauterine insemination (IUI). Our commercialization
strategy involves the opening of dedicated INVO Centers focused on
offering the INVOcell® and IVC procedure (with 3 centers in
North America now operational), as
well as selling our technology solution into existing fertility
clinics. For more information, please visit
www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-participate-in-roundtable-discussion-at-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-301507453.html
SOURCE INVO Bioscience, Inc.